Seeking Alpha

Verastem (VSTM) initiates a Phase 1 trial of the small molecule inhibitor VS-4718 in patients...

Verastem (VSTM) initiates a Phase 1 trial of the small molecule inhibitor VS-4718 in patients with advanced cancer. The treatment targets the focal adhesion kinase pathway of cancer stem cells. The trial should give VSTM "the necessary safety profile and dosing information to determine the future course of clinical development," the company says. (See also: VS-6063 gets Orphan Drug status in Europe)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs